Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 38INDUSTRY 6NETWORK 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms, Plasma Cell 14Lymphoma 14Leukemia 13Burkitt Lymphoma 10Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 5HIV Infections 5Brain Neoplasms 5Acquired Immunodeficiency Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Biphenotypic, Acute 4Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Lung Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Rectal Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Down Syndrome 2Dendritic Cell Sarcoma, Interdigitating 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Melphalan 4sargramostim 3Peripheral Blood Stem Cell Transplantation 3Cyclophosphamide 3Interferon-alpha 2Filgrastim 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 24'-deoxy-4'-iododoxorubicin 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Sunitinib 1Specimen Handling 1Radiotherapy 1Pharmacogenomic Testing 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Ketamine 1Interleukin-12 Subunit p35 1Imatinib Mesylate 1Ifosfamide 1Docetaxel 1Decitabine 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Immunoglobulin Light-chain Amyloidosis × Dexamethasone × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01078454 2022-02-01

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

National Cancer Institute (NCI)

Phase 3 Completed
11 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡